Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422758 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A3KCNH2DRD2KDM4E | |
| SCHEMBL18586634 | 0.86 | SLC6A4 (0.37) | SLC6A4SLC6A3KCNH2L3MBTL1CRHBP | |
| SCHEMBL18619467 | 0.82 | CHRM2 (0.39) | SLC6A4SLC6A3L3MBTL1CRHBPCRHR2 | |
| SCHEMBL8416511 | 0.80 | SLC6A3 (0.51) | SLC6A4SLC6A3KCNH2KDM4EALDH1A1 | |
| SCHEMBL14490103 | 0.76 | DRD2 (0.34) | DRD2CXCR2 | |
| SCHEMBL5407103 | 0.74 | SLC6A3 (0.35) | SLC6A4SLC6A3 | |
| SCHEMBL5407105 | 0.74 | SLC6A3 (0.35) | SLC6A4SLC6A3 | |
| SCHEMBL5402526 | 0.73 | SLC6A4 (0.31) | SLC6A4SLC6A3 | |
| SCHEMBL5402533 | 0.73 | SLC6A4 (0.31) | SLC6A4SLC6A3 | |
| SCHEMBL4693302 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1233968-A2 | TRANSITION METAL-CYCLOPENTADIENYL-TROPANE CONJUGATES | YALE UNIVERSITY (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020111486-A1 | Transition metal-cyclopentadienyl-tropane conjugates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-08-15 | — | — | US | disclosed |
| WO-2001040239-A2 | TRANSITION METAL-CYCLOPENTADIENYL-TROPANE CONJUGATES | YALE UNIVERSITY (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111486-A1 | Transition metal-cyclopentadienyl-tropane conjugates | SLC6A3, SLC18A2, SLC6A2 | SLC6A4 5/4885SLC6A3 1/4885KCNH2 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.